查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961374

免疫腫瘤學檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按適應症、技術、地區和競爭格局分類，2021-2031年

Immuno Oncology Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Technology, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球免疫腫瘤學檢測市場預計將從 2025 年的 54.7 億美元成長到 2031 年的 82.1 億美元，複合年成長率為 7.01%。

這些檢測方法作為專門的分析平台，旨在評估癌細胞與免疫系統之間的相互作用，從而支持免疫療法的研發和患者分層。該市場的成長主要受全球癌症負擔日益加重以及精準醫療發展趨勢的推動，而精準醫療需要可靠的生物標記來指導治療方案的選擇。根據美國癌症協會預測，到2024年，美國將新增2,001,140例癌症病例，這項數據凸顯了開發先進診斷工具以指導治療性介入和改善臨床療效的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 54.7億美元
市場規模：2031年 82.1億美元
複合年成長率：2026-2031年 7.01%
成長最快的細分市場 結腸癌
最大的市場 北美洲

儘管市場成長勢頭強勁，但檢測方法的開發和檢驗需要大量資金投入，這構成了市場面臨的重大障礙。專用試劑和複雜分析平台的高昂成本限制了預算有限的小規模研究機構和醫療機構的取得。這種經濟壁壘阻礙了這些關鍵診斷技術的廣泛應用，並可能減緩成本敏感地區的市場擴張速度。

市場促進因素

對免疫療法研發投入的增加是推動市場成長的主要動力，製藥公司正積極開發抗體藥物複合體和雙特異性抗體等新型治療方法。這些投入推動了對用於標靶檢驗、作用機制研究和臨床試驗監測的專用免疫腫瘤學檢測方法的需求。主要產業參與者優先發展癌症治療產品線，其研發投入規模之大可見一斑。例如，默克公司在2024年2月發布的2023年第四季及全年財報中披露，全年研發支出達到305億美元，這反映出該公司策略性地加強了包括癌症治療產品在內的產品線開發。如此巨額的資本投入確保了對篩檢和表徵不斷擴大的免疫療法候選藥物庫的高複雜度檢測方法的持續需求。

同時，伴隨診斷（CDx）的日益普及正在改變市場格局，因為它在檢測結果和治療決策之間建立了至關重要的聯繫。隨著精準癌症治療逐漸成為標準療法，法規結構也在不斷發展，要求新藥和診斷測試的聯合開發，以確保患者合格並最大限度地提高治療效果。這一趨勢迫使診斷試劑製造商快速創新，將PD-L1和MSI狀態等生物標記整合到強大的臨床平台中。為了支持這一監管趨勢，美國食品藥物管理局（FDA）在其2024年3月發布的《2023年腫瘤監管審查》中明確指出，2023年核准了15項新的腫瘤設備伴隨診斷適應症。此外，主要市場領導的表現也反映了商業性活力。據羅氏公司稱，其診斷部門2023會計年度的基礎業務收入成長了7%，這主要得益於2024年對免疫診斷解決方案的持續需求。

市場挑戰

免疫腫瘤學檢測的研發和檢驗需要大量的資金投入，這成為市場擴張的主要障礙。建構這些專業診斷平台需要大量的研發成本，不可避免地導致終端用戶支付高昂的費用。因此，預算有限的小規模研究機構、地區醫院和醫療機構往往無法負擔這些先進的分析工具和必要的專用試劑。這種經濟差距限制了檢測技術的應用，使其主要局限於資金雄厚的學術機構和大型製藥公司，阻礙了檢測技術在分散環境中的廣泛應用，並減緩了檢測總量的成長。

全球醫療保健生態系統面臨的財政負擔加劇了這項挑戰。決策者被迫將成本控制置於昂貴技術應用之上。這種巨大的經濟壓力限制了可用於診斷技術創新的資金。根據美國癌症研究協會 (AACR) 發布的《2024 年癌症進展報告》，預計 2020 年至 2050 年間，癌症造成的全球累積經濟負擔將達到 25.2 兆美元。如此沉重的財務負擔迫使醫療機構限制資本投資，直接阻礙了成本敏感地區免疫腫瘤檢測市場的成長。

市場趨勢

人工智慧驅動的檢測分析技術的整合，透過提升生物標記解讀的準確性和處理能力，從根本上重塑了全球免疫腫瘤學檢測市場。這些先進的演算法能夠對複雜的組織標記進行自動化定量評估，消除了人工病理診斷中固有的變異性，並有助於對腫瘤微環境進行精確表徵。這些數位化工具的加速應用也體現在該領域領先創新者的財務表現。根據2025年2月《韓國生物醫學評論》的報導《Lunit透過全球擴張與創新實現創紀錄的營收成長》，Lunit公司2024年的營收約為3,720萬美元，較去年同期成長116%。這主要歸功於該公司人工智慧驅動的診斷套件在全球醫療機構的廣泛部署。

同時，基於液態生物檢體的免疫腫瘤學檢測技術的出現，透過實現對治療反應的非侵入性時間序列監測，推動了市場擴張。這些檢測技術透過檢測循環腫瘤DNA，克服了組織樣本獲取的局限性，為微量殘存疾病提供了關鍵訊息，並幫助臨床醫生快速調整免疫治療策略。這種向血液檢測的轉變，在檢測數量激增的推動下，正產生顯著的商業性動力。根據Guardant Health於2025年2月發布的“2024會計年度第四季及全年財務業績”，該公司2024會計年度總收入達到7.39億美元，年增31%。這主要歸功於臨床腫瘤學檢測數量增加了20%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球免疫腫瘤學檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（大腸直腸癌、肺癌、惡性黑色素瘤、膀胱癌等）
    • 透過科技（免疫檢測、聚合酵素鏈鎖反應（PCR）、次世代定序（NGS）、流式細胞技術）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美免疫腫瘤學檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲免疫腫瘤檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區免疫腫瘤檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲免疫腫瘤檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲免疫腫瘤檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球免疫腫瘤檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies, Inc.
  • BIO-RAD LABORATORIES, INC.
  • Charles River Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • NanoString Technologies, Inc.
  • PerkinElmer Inc.
  • QIAGEN NV
  • Sartorius AG
  • THERMO FISHER SCIENTIFIC, INC.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24521

The Global Immuno Oncology Assays Market is projected to expand from USD 5.47 Billion in 2025 to USD 8.21 Billion by 2031, registering a compound annual growth rate (CAGR) of 7.01%. These assays serve as specialized analytical platforms designed to assess the interactions between tumor cells and the immune system, thereby aiding in the development of immunotherapies and patient stratification. The market is driven primarily by the increasing global cancer burden and a simultaneous shift toward precision medicine, which demands reliable biomarkers for treatment selection. As reported by the American Cancer Society, it was projected that 2,001,140 new cancer cases would be diagnosed in the United States in 2024, a statistic that underscores the urgent need for advanced diagnostic tools to guide therapeutic interventions and enhance clinical outcomes.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.47 Billion
Market Size 2031USD 8.21 Billion
CAGR 2026-20317.01%
Fastest Growing SegmentColorectal Cancer
Largest MarketNorth America

Despite this positive growth trajectory, the market encounters a significant hurdle regarding the high financial investment necessary for assay development and validation. The substantial costs linked to specialized reagents and complex analytical platforms restrict access for smaller research institutions and healthcare facilities with constrained budgets. This economic barrier impedes the widespread adoption of these essential diagnostic technologies and may decelerate the pace of market expansion in regions that are sensitive to costs.

Market Driver

Increased investment in research and development for immunotherapy acts as a major catalyst for the market, with pharmaceutical companies aggressively pursuing novel therapeutic modalities such as antibody-drug conjugates and bispecific antibodies. This financial dedication fuels the demand for specialized immuno-oncology assays, which are essential for target validation, mechanism-of-action studies, and clinical trial monitoring. The scale of these efforts is evident in the expenditure of major industry players prioritizing oncology pipelines; for instance, Merck & Co., Inc. reported in its 'Fourth-Quarter and Full-Year 2023 Financial Results' in February 2024 that R&D expenses reached $30.5 billion for the full year, reflecting a strategic intensification of their pipeline development, including oncology assets. Such massive capital infusion ensures a continuous need for high-complexity assays to screen and characterize expanding libraries of immunotherapeutic candidates.

Simultaneously, the rising adoption of companion diagnostics (CDx) is transforming the market landscape by establishing a vital link between assay results and therapeutic decision-making. As precision oncology becomes the standard of care, regulatory frameworks are evolving to require the co-development of diagnostic tests with new drugs to ensure patient eligibility and maximize treatment efficacy. This trend compels diagnostic manufacturers to innovate rapidly, integrating biomarkers like PD-L1 and MSI status into robust clinical platforms. Highlighting this regulatory momentum, the U.S. Food and Drug Administration (FDA) noted in its 'Oncology Regulatory Review 2023' in March 2024 that the agency authorized 15 new companion diagnostic indications for oncology devices in 2023. Furthermore, commercial vitality is reflected in the performance of key market leaders; according to Roche, in 2024, the company's Diagnostics Division achieved a 7% growth in base business sales for the 2023 fiscal year, driven largely by sustained demand for immunodiagnostic solutions.

Market Challenge

The substantial financial investment required for the development and validation of immuno-oncology assays presents a significant barrier to market expansion. Creating these specialized diagnostic platforms involves considerable research and development expenditure, which inevitably leads to high pricing for end-users. Consequently, smaller research institutions, community hospitals, and healthcare facilities with limited budgets are often unable to acquire these advanced analytical tools and the necessary specialized reagents. This economic disparity restricts adoption primarily to well-funded academic centers and major pharmaceutical companies, thereby stifling broader market penetration and slowing the overall volume of testing in decentralized settings.

This challenge is further exacerbated by the financial strain on the global healthcare ecosystem, which compels decision-makers to strictly prioritize cost containment over the acquisition of expensive technologies. This intense economic pressure limits the funds available for diagnostic innovation. According to the American Association for Cancer Research (AACR), in its 2024 Cancer Progress Report, the cumulative economic burden of cancer globally is projected to reach $25.2 trillion between 2020 and 2050. Such profound financial liabilities force healthcare providers to limit capital expenditure, directly hampering the growth of the immuno-oncology assays market in cost-sensitive regions.

Market Trends

The integration of AI-enabled assay analytics is fundamentally reshaping the Global Immuno Oncology Assays Market by improving the accuracy and throughput of biomarker interpretation. These advanced algorithms allow for the automated, quantitative scoring of complex tissue markers, addressing the variability inherent in manual pathology and facilitating the precise characterization of the tumor microenvironment. The accelerating adoption of these digital tools is reflected in the financial performance of key innovators in the sector. According to Korea Biomedical Review, February 2025, in the article 'Lunit achieves record revenue growth driven by global expansion, innovation', Lunit reported a 116% year-over-year revenue increase to approximately $37.2 million in 2024, fueled by the expanded deployment of its AI-powered diagnostic suites across global medical institutions.

Concurrently, the emergence of liquid biopsy-based immuno-oncology assays is driving market expansion by enabling non-invasive, longitudinal monitoring of treatment response. These assays overcome the limitations of tissue availability by detecting circulating tumor DNA, providing critical insights into minimal residual disease and helping clinicians rapidly adjust immunotherapeutic strategies. This shift towards blood-based testing is generating significant commercial momentum as test volumes surge. According to Guardant Health, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company achieved total revenue of $739 million for the fiscal year 2024, marking a 31% increase from the prior year, primarily driven by a 20% growth in clinical oncology test volume.

Key Market Players

  • Agilent Technologies, Inc.
  • BIO-RAD LABORATORIES, INC.
  • Charles River Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • NanoString Technologies, Inc.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Sartorius AG
  • THERMO FISHER SCIENTIFIC, INC.

Report Scope

In this report, the Global Immuno Oncology Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immuno Oncology Assays Market, By Indication

  • Colorectal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Bladder Cancer
  • Others

Immuno Oncology Assays Market, By Technology

  • Immunoassays
  • Polymerase chain reaction (PCR)
  • Next-generation sequencing (NGS)
  • Flow Cytometry

Immuno Oncology Assays Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immuno Oncology Assays Market.

Available Customizations:

Global Immuno Oncology Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immuno Oncology Assays Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Colorectal Cancer, Lung Cancer, Melanoma Cancer, Bladder Cancer, Others)
    • 5.2.2. By Technology (Immunoassays, Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Flow Cytometry)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Immuno Oncology Assays Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Immuno Oncology Assays Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Immuno Oncology Assays Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Immuno Oncology Assays Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Technology

7. Europe Immuno Oncology Assays Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Immuno Oncology Assays Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Technology
    • 7.3.2. France Immuno Oncology Assays Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Technology
    • 7.3.3. United Kingdom Immuno Oncology Assays Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Technology
    • 7.3.4. Italy Immuno Oncology Assays Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Immuno Oncology Assays Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Technology

8. Asia Pacific Immuno Oncology Assays Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Immuno Oncology Assays Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Immuno Oncology Assays Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Immuno Oncology Assays Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Immuno Oncology Assays Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Immuno Oncology Assays Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Technology

9. Middle East & Africa Immuno Oncology Assays Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Immuno Oncology Assays Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Technology
    • 9.3.2. UAE Immuno Oncology Assays Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Technology
    • 9.3.3. South Africa Immuno Oncology Assays Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Technology

10. South America Immuno Oncology Assays Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Immuno Oncology Assays Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Technology
    • 10.3.2. Colombia Immuno Oncology Assays Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Technology
    • 10.3.3. Argentina Immuno Oncology Assays Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Immuno Oncology Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BIO-RAD LABORATORIES, INC.
  • 15.3. Charles River Laboratories, Inc.
  • 15.4. F. Hoffmann-La Roche Ltd
  • 15.5. Illumina, Inc.
  • 15.6. NanoString Technologies, Inc.
  • 15.7. PerkinElmer Inc.
  • 15.8. QIAGEN N.V.
  • 15.9. Sartorius AG
  • 15.10. THERMO FISHER SCIENTIFIC, INC.

16. Strategic Recommendations

17. About Us & Disclaimer